Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
KOSTAIVE® European CHMP opinion expected December Positive results from multiple Phase 3 studies support KOSTAIVE® U.S. BLA filing in H1 2025 Superior 12-month durability results from Phase 3 study of KOSTAIVE® published in The Lancet Infectious Diseases Positive Phase 3 results showed KOSTAIVE® XBB.1.5. met all four primary study objectives and key secondary objectives Investor conference call at 4:30 p.m. ET today SAN DIEGO, November 07, 2024 BUSINESS WIRE )--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided corporate updates. "I am thrilled about the approval of KOSTAIVE® for the COVID-19 JN.1 strain in Japan and for the continued success of the STARR® platform in multiple Phase 3
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $63.00 price target on the stock.MarketBeat
- Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics to Attend Upcoming Investor ConferencesBusiness Wire
ARCT
Earnings
- 11/7/24 - Beat
ARCT
Sec Filings
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- ARCT's page on the SEC website